The Russian Competition Authority approves first two manufacturers on the maximum selling price of medicine favipiravir used in treating COVID-19 and announces that the price registration will increase its availability for the country’s population

FAS: After Favipiravir Price Registration, Its Retail Price Will Be Reduced at Least Twice*

Registering the price of a medicine for treatment of COVID-19 will significantly increase its availability for the Russian population

The FAS Russia has approved the first two pharmaceutical manufacturers on the maximum selling price for the medicine for the treatment of COVID-19 with the international non-proprietary name (INN) favipiravir [1]. The decision to agree on a price of 100 rubles per pill was made by all members of the Commission of the Ministry of Health of Russia on the formation of lists of medicine in the presence of representatives of pharmaceutical manufacturers.

It should be noted that this is the first case when the maximum selling price for a medicine was set by members of the Commission at the stage of including a medicine in the list of vital and essential medicines (VED) [2]. The economic analysis was based on the prices in countries where favipiravir is in circulation.

“At the time of consideration of manufacturers’ applications for the inclusion of favipiravir in the VED list, medicines with this INN were circulating in India and China, including the original medicine Avigan, the price of which is 100 rubles per tablet. This price was discussed as indicative for using in Russia and was supported by all members of the Commission,” Timofey Nizhegorodtsev, Deputy Head of the FAS Russia said.

Thus, after the registration of the maximum selling price for favipiravir, its cost per pack of 50 tablets in the subjects of the Russian Federation will amount to 5,500 rubles, including VAT, excluding regional markups (authorized bodies in the subjects of the Russian Federation independently set the maximum amounts of wholesale and retail markups after approval by the antimonopoly service).

In general, the reduction in the maximum selling price for the medicine was more than 50%, which will increase its availability for the Russian population.

So, if today the retail price for favipiravir in Moscow pharmacies ranges from 11 320 rubles to 16 306 rubles [3], then after registering its maximum selling price, the maximum retail cost of the medicine in the capital, taking into account surcharges, may be 6 875 rubles including VAT (pack of 50 tablets).

It should be reminded that on October 12, 2020, the Decree of the Government of the Russian Federation No. 2626-r was signed on expanding the list of vital and essential medicines, which also included favipiravir [4].

*This is the original title of the press release. The title above has been amended in order to match the e-Competitions format. Individual authors are welcome to provide original independent commentaries on the case law. Articles are subject to approval by the Board of e-Competitions Bulletin before publication based on the Editorial Policy (click here).

Version PDF

Auteur

Citation

Russian Competition Authority, The Russian Competition Authority approves first two manufacturers on the maximum selling price of medicine favipiravir used in treating COVID-19 and announces that the price registration will increase its availability for the country’s population, 21 octobre 2020, e-Competitions October 2020, Art. N° 97414

Visites 138

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues